Study guide
11.3 Conflicts of Interest and Prorated Payments
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
11.3 Conflicts of Interest and Prorated Payments
Key Takeaways Explain This Topic AI
Conflicts can involve financial, professional, family or hierarchical interests.
Disclosure and proportionate management are distinct steps.
Participant payment and sponsor payments to the site are different flows.
Last updated: October 2026
Conflicts of Interest and Prorated Payments
The ECO specifically includes financial interests of investigators/staff and family or site participation in a trial. The monitor should recognise situations needing disclosure and appropriate review, verify that the trial's process was followed and escalate concerns. The CRA should not invent a universal dollar threshold or conclude that any equity holding automatically disqualifies an investigator. Country-specific financial forms and thresholds are outside ACRP's stated examination reference scope.
Disclosure and management
A useful process identifies the relationship, the relevant decision-making role, who reviews it, what safeguards are imposed and when it must be updated. Management can involve independent review, separation of responsibilities, additional oversight or restrictions on participation as appropriate. The responsible institution, sponsor and ethics committee functions determine the applicable measures.
For example, an investigator with a product-related financial interest might also recruit and assess a subjective endpoint. Disclosure alone does not remove the potential influence. Independent assessment or another proportionate control may be needed. Verify the actual plan and evidence of implementation. Do not treat a signed annual form as proof that a later changed interest was captured.
A staff member's family participation creates different concerns: confidentiality, voluntariness, assessment objectivity and access to treatment identity. The appropriate decision depends on the circumstances and reviewed safeguards. A monitor should flag the relationship for responsible evaluation rather than secretly reassigning a participant identifier to conceal it.
Ethics committee independence
E6(R3) expects only committee members independent of the investigator and sponsor to vote or provide an opinion. Investigators or sponsor personnel may provide information but should not participate in the decision. Review appropriate evidence of committee composition and procedures without assuming that an institutional colleague is automatically independent in every particular case.
A conflict can also affect an independent monitoring or adjudication function. A DMC's purpose is undermined if members have operational responsibility for the decisions they are evaluating. Its charter and conflict process should support suitable independence and access. Independence is a functional safeguard; it does not mean that qualified experts can never be compensated for legitimate work.
Participant payment is a separate ethical question
Compensation for time and inconvenience and reimbursement of reasonable expenses can support fair access. They should not pressure a person to accept disproportionate risk or remain against their wishes. E6(R3) calls for ethics review of the amount and method; payment should be timely, prorated and not wholly contingent on completion. The information should be disclosed in the participant materials.
Payment arrangement Question to examine Why it matters
Reimbursement of documented travel Is the method reasonable and accessible? Avoid unnecessary financial barriers
Visit-based compensation Are amount and timing reviewed and explained? Permit fair payment for completed participation
Entire payment withheld until final visit Does withdrawal cause loss of earned payment? Potential pressure to remain
Large additional completion amount Has the ethics committee evaluated influence and context? A simple amount alone does not establish acceptability
Injury treatment/compensation What arrangements and information apply? Distinguish injury protection from participation payment
A worked payment example
Assume an approved schedule provides 40 currency units for each of five completed visits, paid after each visit, and separately reimburses reasonable documented travel. A participant completes three visits and withdraws. The earned participation amount is 3 × 40 = 120 units , plus applicable travel reimbursement. Staff should not withhold the 120 units until the person agrees to visits four and five. The example illustrates proration, not an official payment rate.
Check what the agreement and approved materials actually say. Sponsor payments to the site and participant compensation are different flows. A delayed sponsor invoice does not automatically justify denying a participant payment owed under the approved arrangement. Resolve operational responsibility through the contract and site process rather than making the participant negotiate the sponsor-site dispute.
Monitoring and documentation
Review relevant disclosure records, approval correspondence, payment schedules, actual communications and reported complaints. Preserve confidentiality for financial and personal information. If a concern affects consent or judgement, assess it with the investigator and sponsor/ethics functions, document the response and verify the agreed safeguard. Do not quietly change a disclosure date or rewrite a payment record to make a late process appear timely.
An exam scenario often tests the distinction between recognising a concern and deciding the remedy. The monitor should identify, document, communicate and verify appropriate management. A conflict does not authorise the CRA to take over clinical judgement, and a recruitment target does not override voluntary participation or independent review.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E2A , WMA Declaration of Helsinki, 2024 .